BamSEC and AlphaSense Join Forces
Learn More

Anika Therapeutics Inc.

NASDAQ: ANIK    
Share price (11/22/24): $16.97    
Market cap (11/22/24): $249 million

Material Contracts Filter

EX-10.1
from 8-K 23 pages Cooperation Agreement
12/34/56
EX-10.4
from 8-K 9 pages May 2, 2024 Michael Levitz Re: Transitional Services and Separation Agreement 1. Separation Date; Transition Period
12/34/56
EX-10.2
from 8-K 9 pages Anika Therapeutics, Inc. Executive Retention Agreement
12/34/56
EX-10.1
from 8-K 5 pages Material contract
12/34/56
EX-10.10B
from 10-K/A 13 pages Notice of Grant of Restricted Stock Units Anika Therapeutics, Inc. 2021 Inducement Plan
12/34/56
EX-10.10A
from 10-K/A 13 pages Notice of Grant of Restricted Stock Units Anika Therapeutics, Inc. 2017 Omnibus Incentive Plan
12/34/56
EX-10.14
from 10-K 10 pages Anika Therapeutics, Inc. Executive Retention Agreement
12/34/56
EX-10.8
from 10-K 2 pages Anika Therapeutics, Inc. Restated Director Compensation Policy
12/34/56
EX-10.1
from 8-K 20 pages Anika Therapeutics, Inc. 2017 Omnibus Incentive Plan
12/34/56
EX-10.1
from 8-K 18 pages Cooperation Agreement
12/34/56
EX-10.13
from 10-K 9 pages Anika Therapeutics, Inc. Executive Retention Agreement
12/34/56
EX-10.1
from 8-K 20 pages Anika Therapeutics, Inc. 2017 Omnibus Incentive Plan
12/34/56
EX-10.12
from 10-K 10 pages Material contract
12/34/56
EX-10.10K
from 10-K 13 pages Notice of Grant of Deferred Stock Units Anika Therapeutics, Inc. 2021 Inducement Plan
12/34/56
EX-10.10J
from 10-K 13 pages Notice of Grant of Restricted Stock Units Anika Therapeutics, Inc. 2021 Inducement Plan
12/34/56
EX-10.10I
from 10-K 14 pages Notice of Grant of Non-Qualified Stock Option Anika Therapeutics, Inc. 2021 Inducement Plan
12/34/56
EX-10.8
from 10-K 2 pages Anika Therapeutics, Inc. Restated Director Compensation Policy
12/34/56
EX-10.3C
from 10-K 35 pages Material contract
12/34/56
EX-10.3B
from 10-K 3 pages Material contract
12/34/56
EX-10.3A
from 10-K 36 pages Material contract
12/34/56